Shopping Cart
Total:

$0.00

Items:

0

Checkout View Cart
Your cart is empty
Keep Shopping

First-in-Class KRAS-Degrader Promising in Pancreatic, Lung Cancers



(MedPage Today) — Setidegrasib showed promising efficacy in patients with previously treated advanced KRAS G12D-mutated pancreatic ductal adenocarcinoma (PDAC) or non-small cell lung cancer (NSCLC), results from a phase I trial suggested.
Among…



Source link

0
Show Comments (0) Hide Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments